Research programme: anticancer therapies - Spirogen

Drug Profile

Research programme: anticancer therapies - Spirogen

Alternative Names: GWL-78; LAM156; LAM232; Project P014; Project P021; RMH-41; SG 2285; SG 2897; ZC 207; ZC 423

Latest Information Update: 21 Oct 2013

Price : $50

At a glance

  • Originator Spirogen
  • Class Benzodiazepines; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Oct 2013 Spirogen has been acquired by MedImmune
  • 09 Feb 2011 Compounds from this programme are available for licensing as of 09 Feb 2011. www.spirogen.com
  • 09 Feb 2011 Preclinical development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top